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Abstract
The Sleeping Beauty (SB) transposon system has been successfully used as a gene delivery tool in nonviral and
viral vector platforms. Since its initial reconstruction, a series of hyperactive mutants of SB have been generated.
Questions remain as to whether the enhanced in vitro activities of these SB transposase mutants translate to the
in vivo setting, and whether such increased integration efficiencies will ultimately compromise the safety profile
of the transposon platform by raising the risk of genomic insertional mutagenesis. Herein, we compared the
in vivo impact of a herpes simplex virus (HSV) amplicon-vectored ‘‘wild-type’’ SB transposase (SB10) and a
‘‘hyperactive’’ SB mutant (HSB5), codelivered in utero with the HSVT-bgeo transposable reporter amplicon
vector to embryonic day 14.5 C57BL/6 mice. The SB10 and HSB5 transposases do not disparately affect the
viability and development of injected mouse embryos. Quantitation of brain-resident bgeo expression on
postnatal day 21 revealed that mice receiving HSB5 exhibited only a trending increase in transgene expression
compared with the SB10-infused group, an outcome that did not mirror the marked enhancement of HSB5-
mediated transposition observed in vitro. These findings indicate that in vivo application of hyperactive SB
mutants, although not differentially genotoxic to the developing mouse embryo, does not necessarily provide a
significant therapeutic advantage over the employment of a lesser active SB when delivered in the context of the
HSV/SB amplicon platform.
Introduction
Herpes simplex virus (HSV)-1 amplicon vectors arecapable of efficiently transducing cells comprising the
central nervous system and, thus, have been extensively en-
gineered for gene-based therapeutic modalities targeting
neurological disorders. The utility of the HSV amplicon vec-
tor has been enhanced by the generation of integration-
competent, hybrid versions that facilitate long-term expres-
sion of the delivered transgene (e.g., HSV/AAV, HSV/
Sleeping Beauty). Our laboratory previously demonstrated
that the integration-competent, bipartite HSV/Sleeping Beauty
(SB) amplicon vector system specifically transduced neuron-
ally restricted precursor cells within the fetal mouse brain on
embryonic day 14.5 (E14.5) after intraventricular delivery of
vector particles (Bowers et al., 2006; Peterson et al., 2007). After
transduction, the SB transposase, which is expressed from an
‘‘effector’’ amplicon (termed HSV-SB), efficiently catalyzes
excision of the inverted repeat/direct repeat (IR/DR)-flanked
reporter transgene (T-bgeo) from the ‘‘integrator’’ amplicon
(termed HSVT-bgeo) and stably integrates it at a TA dinu-
cleotide site within the cellular genome. These series of events
have been shown to result in long-term expression of the re-
porter transgene in various regions of the brain, specifically
the cortex, hippocampus, and dentate gyrus, due to subse-
quent proliferation and migration of the stably transduced
neuronal precursor cells. Accordingly, the HSV/SB amplicon
vector system is being developed as a fetal gene delivery
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vector platform capable of targeting the prevalent neuronal
precursor cell population for widespread dissemination of
therapeutic genes to treat early-onset neurological disorders.
Although initial studies have provided proof-of-principle
concerning the feasibility of using the HSV/SB amplicon
vector for stable integration of transgenes in vivo, the impact
of in utero manipulation and stable transduction of neuronal
precursor cells on postnatal survival rates has not been sys-
tematically determined. The HSV/SB amplicon vector plat-
form employed in our initial investigations was designed
with the ‘‘wild-type’’ version of the SB transposase (termed
SB10). Since then, a series of ‘‘hyperactive’’ mutants of SB has
been generated by selectively changing multiple residues
within the SB transposase open reading frame. These mu-
tants exhibit enhanced transposition activity compared with
SB10 in cell line-based transposition assays (Geurts et al.,
2003; Yant et al., 2004; Baus et al., 2005). Consequently, these
hyperactive mutants have been used in gene delivery ap-
plications to enhance the efficiency of transposition as a
means to overcome the limitations associated with plasmid-
based gene delivery in vivo (Yant et al., 2000; Liu et al., 2004,
2006; Aronovich et al., 2007). Questions remain as to whether
the enhanced activity of these SB transposase mutants
observed in vitro in standard immortalized cell lines trans-
lates to the in vivo setting in specific target cell types, and
whether such increased integration efficiencies will com-
promise the safety profile of the transposon platform by
unduly introducing a higher risk of genomic instability.
In this paper we employed the hyperactive HSB5 mutant
transposase, which has been shown to display an *10-fold
higher transposition efficiency than SB10 during plasmid-
based transposition (Yant et al., 2007), as a means to optimize
the current HSV/SB vector platform for more efficient stable
gene transfer and long-term expression of therapeutic genes
in vivo. We sought to determine whether the hyperactivity
observed in vitro with the HSB5 transposase would be ex-
hibited when codelivered in utero with the HSVT-bgeo
transposable reporter amplicon to the developing brain of
E14.5 mouse embryos. In addition, we sought to assess the
safety of using a hyperactive SB transposase to mediate
transposition during mouse brain development and whether
the increased transposition levels observed in vitro would be
detrimental to the survival of the mouse embryo. Our results
indicate that the hyperactive HSB5 mutant transposase
marginally enhanced transgene expression levels in vivo
compared with SB10. Importantly, HSB5 transposase-
mediated transposition in the E14.5 mouse brain did not
unduly affect the viability and development of the embryo
compared with the wild-type SB transposase, which may
help to mitigate safety concerns associated with stable inte-
gration of therapeutic transgenes via HSV/SB amplicons in
the developing brain.
Materials and Methods
Cell culture
The human embryonic kidney (HEK 293) cell line was
obtained from the American Type Culture Collection (ATCC,
Manassas, VA) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) and 10%
fetal bovine serum (Gemini Bio-Products, West Sacramento,
CA) at 378C and 5% CO2.
Amplicon plasmid construction and helper
virus-free packaging
To generate the HSB5 open reading frame (Yant et al.,
2007), the ‘‘wild-type’’ SB10 transposase open reading frame
was codon optimized and synthesized for high-level protein
expression along with four mutations at positions K13A,
K33A, T83A, and S270A (GENEART, Regensburg, Ger-
many). The HSB5 open reading frame was amplified by PCR
from the pGA4-HSB5 plasmid, using primers containing a 50
KpnI site in the forward primer and a 50 SacI site in the
reverse primer. The primer sequences were as follows:
HSB5.Fwd, 50-GCCGCCGGTACCATGGGCAAGAGCAAA
GAGATCAGCCAGGAC-30; HSB5.Rev, 50-GCGCCGAGCTC
TCAGTACTTGGTGGCGTTGCCCTTGAAC-30.
The PCR product was ethanol precipitated, digested se-
quentially with KpnI and SacI, and cloned into the
pHSVPrPUC amplicon plasmid using the corresponding
sites to create the final pHSV-HSB5 vector (Fig. 1A). The
construction of pHSV-SB10 and pHSVT-bgeo has been pre-
viously described (Bowers et al., 2006). The HSV-SB10,
HSV-HSB5, HSVPrPUC, and HSVT-bgeo amplicons were
packaged using a helper virus-free packaging system, which
has been described previously (Bowers et al., 2001).
Cell line-based transposition assays
Transposition efficiency of HSB5 transposase at various trans-
posase-to-transposon amplicon ratios. HEK 293 cells (4105 cells
per well in a 24-well dish) were individually cotransduced
with increasing amounts of HSV-HSB5 viral particles to-
gether with a fixed amount of HSVT-bgeo amplicon to
achieve various transposase-to-transposon amplicon ratios
(0.01:1, 0.05:1, 0.1:1, and 1:1) while maintaining an overall
multiplicity of infection (MOI) of 1. The HSVPrPUC ampli-
con served as a ‘‘balance’’ virus to maintain an MOI of 1
under each condition. On incubation for 1 hr at 378C, the
virus-containing medium was removed and cells were wa-
shed once and replenished with fresh medium. At 48 hr
posttransduction, cells were trypsinized and seeded at a 1:3
dilution in 10-cm dishes containing medium supplemented
with G418 antibiotic (600mg/ml; Invitrogen). Cells were re-
fed every 3–4 days with fresh medium supplemented with
G418 antibiotic. After a 2-week selection period, the resulting
G418-resistant colonies were fixed with 1% glutaralde-
hyde and enumerated after 5-bromo-4-chloro-3-indolyl-b-d-
galactopyranoside (X-Gal) staining (Fig. 1B).
Transposition efficiency of the hyperactive HSB5 transposase.
HEK 293 cells (4105 cells per well in a 24-well dish) were
individually cotransduced for 1 hr at 378C with a 1:1 viral
particle ratio of either HSV-SB10 or HSV-HSB5 together with
the HSVT-bgeo amplicon at an MOI of 1. The HSVPrPUC
amplicon served as an empty vector control. A colony for-
mation assay was performed as described previously (Fig. 2).
In utero amplicon transduction
Under the surgical plane of anesthesia (Avertin, 0.5mg/
ml), the maternal abdomen of postcoitum 14.5 C57BL/6 mice
was shaved and cleansed with povidone-iodine solution USP
(Aplicare, Branford, CT). A laparotomy was performed and
the uterus was gently exteriorized onto a sterile disposable
drape. Two microliters of HSV-SB10, HSV-HSB5, or the
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control amplicon HSVPrPUC was mixed at a viral particle
ratio of 1:1 (2ml of total volume of virus, 2104 total trans-
ducing units) with HSVT-bgeo and delivered via a glass-
pulled pipet to each embryo intracranially, using an IM300
programmable microinjector (Narishige International, East
Meadow, NY). Once born, the pups were allowed to develop
to 21 days of age, killed, and brains were processed for im-
munohistochemical and integration site analyses.
Immunohistochemistry
b-Galactosidase-specific staining. The left hemisphere of each
brain cotransduced with the HSV amplicon combinations
(HSV-SB10 plus HSVT-bgeo, HSV-HSB5 plus HSVT-bgeo,
and HSVPrPUC plus HSVT-bgeo) was analyzed 21 days
postpartum by immunocytochemistry. Processing of tissue
and mounting on glass slides were performed as described
previously (Bowers et al., 2006). Double immunohistochem-
istry was performed on coronal mouse brain sections (30mm)
using anti-b-galactosidase, rabbit IgG fraction (diluted
1:2000; Biodesign, Saco, ME), with anti-NeuN mouse
monoclonal antibody (diluted 1:200; Millipore, Billerica, MA)
or anti-GFAP–Cy3 conjugate monoclonal antibody clone G-A-
5 (diluted 1:2000; Sigma-Aldrich, St. Louis, MO). An Alexa 488
anti-rabbit IgG (HþL, diluted 1:200; Invitrogen) fluorescent
secondary antibody was subsequently used. Immunopositive
cells were visualized with a FV1000 Olympus laser scanning
confocal microscope (Olympus, Center Valley, PA) at a
magnification of 40. Quantification of the average pixel
density of b-galactosidase-specific cell staining in the visual
motor cortex region (VM) was performed by diaminobenzi-
dine (DAB) staining as described previously (Bowers et al.,
2006). b-Galactosidase-specific cell staining in the VM region
was determined with an Olympus AX-70 microscope equip-
ped with a motorized stage and MCID 6.0 Elite software
(Interfocus imaging subsidiary of GE Healthcare, Cambridge,
UK). An average of eight equivalent sections of the VM region
per mouse were analyzed at a magnification of20.
Nissl staining. Brain sections were mounted on Superfrost
Plus slides (VWR International, West Chester, PA) and al-
lowed to dry completely. Thereafter, the slides were
hydrated in distilled H2O for 5min, and stained with 0.02%
FIG. 1. Determination of the optimal ratio of HSV-HSB5 to HSVT-bgeo amplicon to achieve maximal SB-mediated trans-
position in vitro. (A) Schematic representation of the amplicons used in the in vivo testing of the HSV/SB amplicon vector
platform. The HSVPrPUC amplicon contains a multiple cloning site, and serves as an empty vector control. The HSV-SB10
amplicon expresses the ‘‘wild-type’’ SB transposase, whereas the HSV-HSB5 amplicon expresses the ‘‘hyperactive’’ HSB5
transposase. HSVT-bgeo serves as a substrate vector for the transposase, and contains an IR/DR-flanked Rous sarcoma virus
(RSV) promoter-driven b-galactosidase–neomycin phosphotransferase fusion reporter gene unit (b-geo; adapted from Bowers
et al., 2006). (B) Assessment of the optimal transposase-to-transposon (HSV-HSB5:HSVT-bgeo) amplicon ratio required to
achieve maximal transposition efficiency. HEK 293 cell monolayers were individually cotransduced with various ratios of
HSV-HSB5 and HSVT-bgeo viral particles at an MOI of 0.5. HSVPrPUC was used as a ‘‘balance’’ virus to ensure that equal
numbers of viral particles were transduced under each condition. Two days posttransduction, the cells were seeded onto 100-
mm dishes at a 1:3 dilution and placed under G418 selection for 2 weeks. G418-resistant colonies were enumerated by X-Gal
histochemistry. Error bars represent the standard error of the mean and statistical analysis was conducted by Student t test.
Color images available online at www.liebertonline.com/hum.
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cresyl violet acetate in 0.25% acetic acid for 30min. De-
staining was conducted by washing the slides in three
changes of distilled H2O and placed in 50% ethanol and 70%
ethanol for 1min each, consecutively. The slides were al-
lowed to dry and dipped in xylene before being cover-
slipped.
Microglial/macrophage staining. Immunohistochemical
staining of brain-resident microglia/macrophages was per-
formed with an anti-Iba-1 rabbit polyclonal antibody (1:750
dilution; Wako, Richmond, VA) in combination with a bio-
tin-conjugated secondary antibody (1:1000 dilution; Vector
Laboratories, Burlingame, CA). DAB staining was conducted
according to the manufacturer’s recommendations, using an
avidin–biotin complex and nickel-enhanced diaminobenzi-
dine (VECTASTAIN ABC system; Vector Laboratories).
Quantification of the number of Iba-1-positive microglial/
macrophage cells was conducted with an Olympus AX-70
microscope equipped with a motorized stage and MCID 6.0
Elite imaging software (Interfocus imaging subsidiary of GE
Healthcare). Six equivalent sections of the VM cortex and
hippocampus region were separately counted and averaged
per mouse at a magnification of20 (n¼ 3 mice per group).
Statistical analysis
Statistical analysis was performed by Student t test and
one-way analysis of variance.
Integration site mapping and analysis
Transposon–genomic DNA junctions were determined by
linear amplification-mediated PCR (LAM-PCR) as described
earlier (Ma´te´s et al., 2009), with the following modifications.
Genomic DNA (500 ng) was subjected to 100 cycles of linear
amplification PCR in a final volume of 50ml with a 50-biotin-
labeled, transposon-specific primer, under the following
conditions: 948C for 1min, 598C for 30 sec, and 728C for 1min
30 sec, and the products were captured on magnetic strep-
tavidin beads (Dynabeads kilobase binder kit; Invitrogen).
After second-strand synthesis, the DNA samples were di-
gested with MboI (New England BioLabs, Ipswich, MA) to
create compatible ends for linker ligation. Ligation reactions
were performed with 50 pmol of the corresponding linkers
overnight at room temperature. The ligation products were
collected on a magnetic separator and resuspended in 10 ml of
Tris-EDTA (TE) buffer. Two microliters of ligation product
was amplified in the primary PCR in a 50-ml total volume,
using a nested transposon-specific primer with the MboI
linker-specific primer, under the following conditions: 948C
for 3 min; 35 cycles of 948C for 30 sec, 588C for 30 sec and
728C for 1 min; followed by 728C for 5min. One microliter of
the PCR product was further amplified in a nested round of
PCR using a nested transposon-specific primer in combina-
tion with an MboI linker-specific nested primer. Conditions
for the nested PCRs were as follows: 948C for 3 min; 35 cycles
of 948C for 30 sec, 558C for 30 sec, and 728C for 1 min; fol-
lowed by 728C for 5min. PCR products were purified with a
PCR purification kit (Qiagen, Hilden, Germany), and char-
acterized by electrophoresis on a 1.25% agarose gel. The
purified PCR product was cloned into the pGEM-T Easy
vector (Promega, Madison, WI), and the DNA sequence was
determined by standard sequencing technology (ABI 3730xl;
Applied Biosystems, Foster City, CA). The identity and lo-
cation of mouse chromosomal sequences that flank the in-
tegrated T-bgeo transposon were mapped by mouse BLAT
genomic alignment ( July 2007, NCBI37/mm9) on the Uni-
versity of California, Santa Cruz (UCSC) genome browser
(available at http://genome.ucsc.edu).
Results
Cell line-based assessment of HSB5 transposase
hyperactivity in the context of an HSV/SB
amplicon vector
Previous plasmid-centric studies have established that, be-
cause of the stoichiometric nature of the transposition reac-
tion, an optimal transposase-to-transposon plasmid ratio must
be used to achieve maximal transposition, and to obviate
the effect of ‘‘overproduction inhibition’’ (Zayed et al., 2004).
The latter effect is common to a number of transposons re-
presenting different families, and is a result of high transpo-
sase levels relative to the transposon within the host cell that
leads to dampening of the transposition (Hartl et al., 1997). We
initially sought to test various transposase-to-transposon
amplicon ratios to determine the optimal ratio that would
facilitate efficient HSB5-mediated transposition from the HSV
amplicon vector. A colony formation assay was performed by
cotransducing HEK 293 cells with a fixed number of HSVT-
bgeo amplicon particles and various amounts of the ‘‘hyper-
active’’ HSB5 transposase expressing HSV amplicon. The
HSVPrPUC amplicon served as an empty vector control and
also as a ‘‘balance’’ virus to ensure that equal numbers of viral
particles were being transduced under each condition. Sche-
matic diagrams of the empty vector control (HSVPrPUC),
effectors (HSV-SB10 and HSV-HSB5), and integrator (HSVT-
bgeo) amplicons used in this study are presented in Fig. 1A.
Cotransduction of HSV-HSB5 and HSVT-bgeo at a 1:1 am-
plicon ratio proved to be optimal, giving rise to the highest
number of G418-resistant colonies (Fig. 1B).
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FIG. 2. Comparison of the transposition efficiency of HSB5
transposase and wild-type SB10 transposase in human em-
bryonic kidney 293 (HEK 293) cells. HEK 293 cells were co-
transduced with HSV-SB10, HSV-HSB5, or HSVPrPUC
amplicon together with the HSVT-bgeo reporter amplicon at
a 1:1 amplicon ratio (MOI of 1). Two days later the cells were
trypsinized and seeded at a 1:3 dilution onto dishes con-
taining medium supplemented with G418 antibiotic (600mg/
ml). Two weeks later G418-resistant colonies were fixed,
stained with X-Gal, and enumerated. Error bars represent the
standard error of the mean and statistical analysis was con-
ducted by Student t test.
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Next, we compared the transposition efficiency of the
hyperactive HSB5 transposase to that catalyzed by the wild-
type SB10 transposase, using the optimized 1:1 transposase-
to-transposon amplicon ratio. Cotransduction of HSV-SB10
plus HSVT-bgeo resulted in an *25-fold increase in the
number of G418-resistant HEK 293 colonies compared with
the HSVPrPUC plus HSVT-bgeo negative control group (Fig.
2). The cotransduction of HSV-HSB5 together with HSVT-
bgeo resulted in a further increase in the number of G418-
resistant colonies, which corresponded to a 3.5-fold increase
in transposition efficiency compared with HSV-SB10. This
result confirmed that the HSB5 transposase was significantly
more active than SB10 in the context of an HSV/SB amplicon
vector, but this gap in transposition activity is lower than
the *10-fold difference observed between HSB5 and SB10
during plasmid-based transposition (Yant et al., 2007).
Comparison of mouse survival rates, brain
architecture, and brain-resident inflammation
after in utero vector infusion
To determine whether the increased transposition activity
of the HSB5 transposase observed in vitro would be pre-
served in an in vivo experimental setup, a total of*2–4104
HSV amplicon vector particles containing an optimized 1:1
amplicon ratio of HSV-SB10 plus HSVT-bgeo, HSV-HSB5
plus HSVT-bgeo, or HSVPrPUC plus HSVT-bgeo was in-
fused intraventricularly into E14.5 C57BL/6 embryos (Fig. 3).
After surgery, the transduced embryos were allowed to
reach full term and the numbers of live births were recorded
to ascertain the survival rate of the mice on postnatal day 0
(P0) and P21. Mice injected with the HSV-HSB5 plus HSVT-
bgeo amplicon combination exhibited a slightly higher
survival rate (65.9%) than the wild-type HSV-SB10 plus
HSVT-bgeo group (47%) and the HSVPrPUC plus HSVT-
bgeo group (45%) on P0, although these differences did not
reach statistical significance (Table 1). In addition, the num-
bers of live births from each cohort reaching P21 were not
significantly different (Table 1). Mice surviving to P21 were
subsequently killed and perfused, and brains were processed
for histochemical analyses. Nissl staining was performed to
assess overall brain architecture. Rostral-to-caudal assess-
ment of 30-mm coronal brain sections did not reveal any
gross abnormalities at the anatomical level (Fig. 4), thus in-
dicating that brain development was not significantly af-
fected after in utero HSV/SB vector transduction. In
aggregate, these data indicate that the use of a hyperactive
form of the SB transposase within the HSV/SB amplicon
vector platform context does not deleteriously affect the vi-
ability or brain development of the embryo as compared
with the wild-type SB10 transposase. Furthermore, because
the empty vector control group (HSVPrPUC plus HSVT-
bgeo) exhibited a survival rate similar to that of the HSV/SB
amplicon vector groups on P0 and P21, it suggests that
the observed impact on mouse survival is not due to SB-
mediated transposition, but is most likely due to complica-
tions arising from in utero surgical manipulation and/or the
exposure of the embryo to helper virus-free HSV amplicons.
We subsequently assessed whether in utero delivery of the
HSV/SB vector system and transposition within the fetal
mouse brain would trigger differential inflammatory re-
sponses. We postulated that such inflammatory responses
would be revealed by increases in microglia/macrophage
activation marker staining patterns in the injected mouse
brain on P21. Microglia are brain-resident macrophages
that are activated and recruited to sites of inflammation
within the brain as a primary participant in innate responses
(Gehrmann et al., 1995). Brain sections were subjected to Iba-1-
specific immunostaining to determine the overall presence
of microglia/macrophages. Equivalent levels of Iba-1-specific
FIG. 3. Schematic representation of the in utero surgical paradigm used for the delivery of HSV/SB amplicon vector
platform to the developing mouse brain. Under the surgical plane of anesthesia (Avertin, 0.5mg/ml), the maternal abdomen
of postcoitum 14.5 C57BL/6 mice was shaved and an incision was made to exteriorize the uterus onto a sterile disposable
drape. Sterile gauze was placed over the exposed uterus and hydrated with lactated Ringer solution. The appropriate virus
combination was mixed at a ratio of 1:1 (total volume, 2ml; total transducing units, 2104) and delivered to each embryo
intraventricularly, using a microinjector. The uterus was placed back into the abdomen and the incision was sutured by
interrupted stitching. The virus-infused embryos were allowed to reach full term and left under maternal care for 21 days
postpartum, at which time they were killed and the brains were processed for immunohistochemistry (left hemisphere) and
integration site analysis (right hemisphere). Color images available online at www.liebertonline.com/hum.
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microglial/macrophage staining were observed throughout
the brain in all three groups of mice injected with HSV-SB10,
HSV-HSB5, or HSVPrPUC plus the HSVT-bgeo reporter am-
plicon (Fig. 5). Quantitative analysis of the pixel density of
Iba-1-specific microglia/macrophage staining in the visual
motor (VM) cortex and hippocampal regions of the mice re-
vealed comparable levels across the three groups of mice on
P21 (n¼ 3 mice per group; Fig. 5J), thus confirming that SB-
mediated transposition and resultant bgeo transgene expres-
sion did not lead to differential effects on microglial activation
amongst the treatment groups.
Both HSV-HSB5 and HSV-SB10 lead to neuronally
restricted transgene expression after intraventricular
coinfusion with HSVT-bgeo into fetal mouse brain
Previous studies using HSV-SB10 had established that the
presence of b-galactosidase (b-Gal) transgene expression in
the mouse brain on P21 was a result of SB-mediated inte-
gration of the T-bgeo reporter transgene in the mouse ge-
nome, because b-Gal expression from the episomally
retained HSVT-bgeo amplicon was undetectable in the ab-
sence of SB transposase (Bowers et al., 2006). Furthermore,
b-Gal expression on P21 was restricted to NeuN-positive
mature neurons, which was subsequently shown to be a
result of the HSV amplicon-specific transduction of neuronal
precursor cells present in the subventricular zone of the de-
veloping fetal brain at E14.5 (Peterson et al., 2007). To de-
termine whether use of the hyperactive HSB5 mutant altered
the cell type specificity of transgene expression, we per-
formed immunohistochemistry on brain sections of killed
P21 mice. As depicted by the representative photomicro-
graphs in Fig. 6, expression of b-Gal (green) was readily
observed in cortical neurons that stained positive for the
neuron-specific marker NeuN (red) in mice infused with
HSV-SB10 plus HSVT-bgeo (Fig. 6A–C) or HSV-HSB5 plus
HSVT-bgeo (Fig. 6D–E). Transgene-positive neurons were
also detected in the hippocampus and dentate gyrus of these
Table 1. Comparison of Survival Rates for C57BL/6 E14.5 Embryos Coinjected In Utero with
HSV-HSB5, HSV-SB10, or HSVPrPUC Along with HSVT-bgeo Reporter Amplicon
Group
Amplicon
combination
No. of E14.5
embryos injected
No. of live
births (P0)
Postsurgery
survival rate
at P0 (%)
No. of P0
Pups that
lived to P21
Postbirth
survival rate
(P21) (%)
1 HSV-HSB5þHSVT-bgeo 44 29 65.9 20 68.9
2 HSV-SB10þHSVT-bgeo 59 28 47 16 57
3 HSVPrPUCþHSVT-bgeo 31 14 45 9 64.3
E14.5, embryonic day 14.5.
FIG. 4. Representative Nissl-stained
brain sections from P21 mice after
in utero, intraventricular vector trans-
duction. At 21 days of age, vector-
transduced animals were killed and
perfused with 4% paraformaldehyde,
and brain sections (30 mm) were pro-
cessed for Nissl staining to assess
overall brain architecture, using an
inverted microscope. A rostral-to-
caudal display of representative P21
mouse brain sections corresponding to
each of the treatment groups [HSV-
HSB5 plus HSVT-bgeo (A–C), HSV-
SB10 plus HSVT-bgeo (D–F), and
HSVPrPUC plus HSVT-bgeo (G–I)] is
presented. Images were captured at
about 0.6mm bregma (A, D, and G),
about –1.3mm bregma (B, E, and H),
and about –3.1 bregma (C, F, and I)
coordinates. Photomicrographs were
obtained at an original magnification
of1.25. Scale bar (A): 2mm.
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cohorts (data not shown). As expected, b-Gal expression was
not detected in mice injected with HSVPrPUC plus HSVT-
bgeo (Fig. 6G–I). Immunohistochemical costaining for a glia-
specific marker, glial fibrillary acidic protein (GFAP), and b-Gal
revealed no apparent colocalization of b-Gal expression
(green) with GFAP-positive astrocytes (red; Fig. 6J–R). Overall,
these results are consistent with previous findings, and indi-
cate that the cell specificity of transgene expression on P21 is
not influenced by the in vitro-ascribed hyperactivity of HSB5.
In utero codelivery of HSV-HSB5 or HSV-SB10 with
HSVT-bgeo results in comparable levels of transgene
expression on P21
We subsequently quantified the level of b-Gal expression
in the three groups of mice to assess whether the hyperactive
HSB5 transposase was more efficient in generating trans-
gene-positive neurons compared with SB10. The level of
b-Gal expression was quantified by determining the average
pixel density of b-Gal-specific diaminobenzidine (DAB) im-
munostaining present in the VM cortex region of each brain.
The VM cortex was selected, because it consistently revealed
the highest level of b-Gal staining in the brain on P21. Mice
intraventricularly infused with either HSV-SB10 plus HSVT-
bgeo or HSV-HSB5 plus HSVT-bgeo exhibited significantly
higher average pixel density of b-Gal/DAB staining than the
HSVPrPUC plus HSVT-bgeo control group (Fig. 6S). Mice
that were infused with HSV-HSB5 plus HSVT-bgeo did show
a trending increase in the level of b-Gal/DAB immuno-
staining as compared with the HSV-SB10 plus HSVT-bgeo
group, although these differences did not reach statistical
significance. Our in vivo findings are in contrast to what
was shown in cell line-based tests (Fig. 2), indicating that
the hyperactive HSB5 transposase mutant does not confer a
marked advantage in the context of the HSV/SB amplicon
vector platform when delivered in utero.
Identification of chromosomal integration sites
of the T-bgeo transposable transgene
in intraventricularly infused mouse brain
To confirm bona fide SB-mediated transposition in the
mouse brain, linear amplification-mediated PCR (LAM-PCR)
analysis was used to map the flanking mouse chromosomal
FIG. 5. Microglial/macrophage
staining pattern in mouse brain on
P21 after in utero HSV/SB vector
transduction. Immunostaining of
brain-resident microglia/macrophage
was performed according to an Iba-1-
specific diaminobenzidine (DAB)
protocol. A rostral-to-caudal display
of representative P21 mouse brain
sections corresponding to each of the
treatment groups [HSV-HSB5 plus
HSVT-bgeo (A–C), HSV-SB10 plus
HSVT-bgeo (D–F), and HSVPrPUC
plus HSVT-bgeo (G–I)] is presented.
Photomicrographs (A), (D), and (G)
correspond to the M1 region of the
motor cortex; (B), (E), and (H) corre-
spond to the CA1 region of the hip-
pocampus (about –1.58mm bregma);
and (C), (F), and (I) correspond to the
dentate gyrus region (about –2.46mm
bregma). Photomicrographs were
obtained at an original magnification
of 10. Scale bar (A): 500mm. Each
inset [in (C), (F), and (I)] represents a
digitally magnified (20) image of
the photomicrograph for better visu-
alization of stained cell morphology.
The number of Iba-1-positive micro-
glia was counted within the visual
motor (VM) cortex and hippocampal
region of the brain, using an Olympus
AX-70 microscope equipped with a
motorized stage and MCID 6.0 Elite
software (J). Six equivalent sections of
the VM cortex and hippocampus re-
gion were separately counted and
averaged per mouse at a magnifica-
tion of 20 (n¼ 3 mice per group).
Error bars represent the standard
error of the mean and statistical anal-
ysis was conducted by Student t test.
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sequences at T-bgeo integration sites in a subset of mice in-
fused with HSV-SB10 plus HSVT-bgeo or with HSV-HSB5
plus HSVT-bgeo. Bona fide SB-mediated transposition is
characterized by integration of the transposon into chromo-
somal TA dinucleotide sites, which are duplicated after in-
tegration (Ivics et al., 1997). Transposon–chromosome
junction sequences containing the molecular signature of SB-
mediated transposition were identified (Table 2). The flank-
ing mouse chromosomal sequences were subjected to BLAT
genomic alignment against the UCSC mouse genome data-
base to map the chromosomal locations of the integrated
T-bgeo transposons. As indicated in Table 2, we were able to
recover two or three insertion sites per mouse in both
treatment groups. In aggregate, these results indicate that
intraventricular delivery of both the wild-type and hyper-
active versions of the HSV/SB amplicon vector platforms at
E14.5 leads to bona fide SB-mediated transposition within
the mouse brain genome.
Discussion
In this study we assessed the in vivo impact of using a
‘‘hyperactive’’ mutant of SB transposase (HSB5) to optimize
the HSV/SB vector for efficient transgene integration in the
developing mouse brain. Interestingly, we found that the
extent of hyperactivity exhibited by the HSB5 transposase
in vitro is not maintained in vivo when used in the context of
the HSV/SB amplicon vector, and appeared to be marginally
advantageous over the use of the ‘‘wild-type’’ SB trans-
posase. Further in vivo evaluation confirmed that HSB5-
FIG. 6. Immunohistochemical analysis and quantification
of the cell type-specific expression of the T-bgeo transgenon
(i.e., a transposable transgene) on P21 after in utero delivery.
At 21 days of age, transduced animals were killed and per-
fused with 4% paraformaldehyde, brain sections were
processed for dual b-galactosidase (b-Gal)/NeuN immuno-
histochemistry, and sections were imaged by confocal mi-
croscopy. Representative brain sections corresponding to the
cortex are depicted. b-Gal-specific staining resulting from T-
bgeo transgenon-mediated expression appears in the green
channel (A, D, and G), NeuN-positive mature neurons in the
red channel (B, E, and H), and colocalized staining (Merged)
appears as yellow (C, F, and I). Similarly, brain sections were
processed for dual b-Gal/GFAP immunohistochemistry (J–
R). The GFAP-positive astrocytes appear in the red channel.
Photomicrographs were obtained at an original magnifica-
tion of 40. Scale bar (A): 200 mm. b-Gal-specific diamino-
benzidine (DAB) immunostaining was conducted on coronal
brain sections of the left hemisphere to quantify the average
pixel density of b-galactosidase-positive neurons in the vi-
sual motor cortex (VM) region of mice that were coinjected
with HSV-SB10, HSV-HSB5, or HSVPrPUC along with the
HSVT-bgeo amplicon (S). b-Gal-positive cells in the VM re-
gion were enumerated with an Olympus AX-70 microscope
equipped with a motorized stage and MCID 6.0 Elite soft-
ware. An average of eight equivalent sections of the VM
region per mouse were analyzed at a magnification of
20. Error bars represent the standard error of the mean
and statistical analysis was conducted by Student t test.
*Statistically significant difference between the two HSV-SB
amplicon (SB10 and HSB5) plus HSVT-bgeo-injected groups
and the HSVPrPUC plus HSVT-bgeo control group
( p< 0.05).
‰
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mediated transposition within neuronal precursor cells of the
embryonic brain did not unduly affect the viability of the
embryo and allowed for normal brain development without
eliciting an adverse immune response; outcomes that help to
mitigate the safety concerns of in utero gene therapy.
Hyperactive mutants of SB transposase were initially de-
veloped with the intention of increasing the in vivo trans-
position efficiency of SB-based nonviral vector platforms,
because in vivo testing of the first-generation SB vector sys-
tem did not exhibit therapeutically beneficial levels of
transgene integration (Yant et al., 2000; Baus et al., 2005).
Although the enhanced transposition efficiency of these
mutants has been validated in cell culture, their efficiency
in vivo has not been fully tested. HSB5 transposase is one
such mutant that has been shown to enhance plasmid-based
transposition by*10-fold compared with the first-generation
wild-type SB10 transposase in cell line-based testing (Yant
et al., 2007). However, the testing of HSB5 in the context of
the HSV/SB vector resulted in an *3.5-fold increase in
transposition efficiency relative to SB10 in HEK 293 cells (Fig.
2). We speculate that the disparity between our result and
that of Yant and colleagues might be due to the following: (1)
intrinsic differences in plasmid-based transposition versus
amplicon-based transposition (de Silva et al., 2010); (2) the
use of different reporter transposable units, with T-bgeo
approximately three times the sequence length of the T-neo
transposon used by Yant and colleagues; and (3) inherent
differences between the two human cell lines used to assess
transposition efficiency.
The mutations resident in the HSB5 transposase have been
postulated to stabilize the synaptic complex during transposi-
tion, thereby increasing the efficiency of the reaction (Yant et al.,
2007). Thus, the failure to observe an increase in b-Gal-specific
DAB immunostaining in the presence of the HSB5 transposase
(Fig. 6S) in vivo may be due to the following: (1) the in vitro-
optimized ratio of HSV-HSB5 to HSVT-bgeo amplicon used in
our studymaybe suboptimal inneuronalprecursor cells in vivo,
because Yant and colleagues and Liu and colleagues had pre-
viously shown that different target tissue types (e.g., mouse
liver and lung) required diverse transposon-to-transposase
plasmid ratios for efficient transposition (Yant et al., 2000; Liu
et al., 2004); (2) the neuronal precursor cell environment in the
fetal mouse brain may lack an unknown cofactor normally
present in immortalized cell lines that facilitates enhanced
transposition byHSB5; and (3) the absence of selective pressure
in vivo may differentially affect SB-mediated transposition via
hyperactive mutants compared with a cell culture setting in
which antibiotic selection is used to select for cells that have
undergone transposition.
During its initial characterization, SB was shown to catalyze
transposition in mouse embryonic stem cells (Luo et al., 1998),
which provided the opportunity to match the transgene-
integrating power of SB with the multipotent, proliferative
nature of stem cells for widespread transgene delivery.
Accordingly, the HSV/SB amplicon vector platform has pro-
ven to be capable of mediating transposition in neuronal
precursor cells in vivo as evidenced by the widespread ex-
pression of b-Gal observed in the brains of mice on P21. The
identification of transposon integration sites within the mouse
genome revealed precise integration of the entire T-bgeo
transposon into TA dinucleotide sites mediated by the wild-
type SB transposase as well as the hyperactive HSB5 trans-
posase, which is a testament to the efficiency of this
integrating system (Table 2). It should be noted that we were
able to recover only two or three integration sites from each
mouse because of technical difficulties associated with map-
ping integration sites in the mouse brain genome. However,
we speculate that more integration sequences, below the limit
of detection, may be present in these mouse genomes. On the
basis of previous studies by our laboratory it is possible that
clonal expansion of the stably transduced neuronal precursors
occurred during mouse brain development, which would
have increased the probability of recovering integration sites
from those specific clonal populations by LAM-PCR. These
limited numbers of flanking mouse chromosomal sequences
revealed that integration had occurred in nontranscriptionally
active regions (data not shown). Even though many more
integration sites will need to be mapped to characterize SB
transposition in the context of the HSV/SB system, SB trans-
position out of plasmids clearly established a fully random
insertional profile at the genome level (Vigdal et al., 2002; Yant
et al., 2005; Mates et al., 2009), suggesting that SB might be
safer than lentiviral and retroviral vectors, which have been
shown to integrate into transcriptionally active genomic sites.
Another aim of this study was to assess the in vivo impact
of using a hyperactive SB transposase in the context of the
HSV/SB amplicon vector platform delivered in utero on
E14.5. Our findings confirm that SB-mediated transposition
did not unduly affect the viability of the mouse embryo
(Table 1), and appeared to be innocuous during subsequent
mouse brain development (Fig. 4). As seen in Table 1, the
invasiveness of the surgical procedure itself resulted in
Table 2. Chromosomal Integration Sites of T-bgeo Transposon in Mouse Brain Genome After
Intraventricular Infusion with HSV-HSB5 or HSV-SB 10 Together with HSVT-bgeo Amplicon
Mouse no. Amplicon combination Flanking chromosomal sequences Mouse chromosome location
SB10_15C HSV-SB10þHSVT-bgeo 1). . .cttcaaCTGTA-TTTGCCAGTGACTTGGA Chr2: 169384664-169384689
2). . .cttcaaCTGTA-AACGCTTAAGAGTACCC Chr1: 123400272-123400310
SB10_15E HSV-SB10þHSVT-bgeo 1). . .cttcaaCTGTA-AGTTCAAGTATGAACAG Chr4: 148872819-148873108
2). . .cttcaaCTGTA-AATGCCAGTGACTTCGG Chr10: 92289486-92289531
3). . .cttcaaCTGTA-TGTGTATGTGGGGTGTG Unknown
HSB5_A2 HSV-HSB5þHSVT-bgeo 1). . .cttcaaCTGTA-TATATACATATATATAT Chr17: 91176203-91176234
2). . .cttcaaCTGTA-TCTAGCCTTCACTGCAA Unknown
3). . .cttcaaCTGTA-AGTGCCCGTGGTTTCAT ChrX: 164815384-164815403
HSB5_C HSV-HSB5þHSVT-bgeo 1). . .cttcaaCTGTA-TTCCCTTATGCCCAGCA Unknown
2). . .cttcaaCTGTA-TTCTACAGTGTCCTGGA Chr11: 9876902-9876922
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fatalities in all three groups of mice on P0 injected with the
HSVT-bgeo amplicon in the presence or absence of SB
transposase. We observed that the survival rate of the
transduced embryos on P0 was also dependent on the
number of embryos present in the pregnant female mouse.
Pregnant female mice bearing 6 or 7 embryos exhibited a
higher birth rate after in utero surgery compared with those
bearing 9 or 10 embryos (data not shown). Unlike stereotactic
surgery, by which the viral vector can be delivered precisely
into the adult brain on the basis of bregma coordinates, un-
guided delivery of the HSV amplicon virus into the ven-
tricular space of the developing embryo on E14.5 is
associated with a certain degree of inaccuracy, which could
also have contributed to a subset of the observed fatalities.
Thus, as described by Punzo and colleagues, ultrasound-
guided in utero gene transfer can be adopted to minimize the
fatalities that occur during surgery (Punzo and Cepko, 2008).
Besides the survival rate on P0 after virus transduction, we
were also interested in the survival rate of these mice on P21
to assess whether SB-mediated transposition during fetal
development would cause any detrimental effects that
manifest themselves after birth. On the basis of our results,
we did not observe an increased fatality rate when the HSV/
SB platform was transduced compared with the empty vec-
tor control group (HSVPrPUC plus HSVT-bgeo), which
suggested that SB-mediated transposition was not a signifi-
cant contributing factor in the deaths that occurred after
birth. The fatalities that did occur after birth (i.e., within 24–
48 hr) in all three groups of mice appeared to be due mainly
to rejection and neglect of the pups by the dam. It remains
unknown whether these deaths were due to developmental
defects caused by the introduction of the virus during em-
bryo development. Although the integration profile of SB has
been shown to have no significant bias toward transcrip-
tionally active regions within the human genome (Yant et al.,
2005), the possibility still exists for insertional mutagenesis
and the development of malignancies. The current study did
not assess the potential for the development of brain tumors,
but it should be noted that we have not observed the pres-
ence of any brain tumors in mice even after 90 days after
stable transduction of neuronal precursor cells by the first-
generation HSV/SB vectors (W.J. Bowers and H.J. Federoff,
unpublished observation). Careful characterization of newly
generated hyperactive mutants of SB transposase is war-
ranted in an in vivo setting to ensure that the integration
profile has not been skewed toward transcriptionally active
sites. Current efforts have also focused on using hyperactive
mutants of the SB transposase to generate site-specific chi-
meric versions to target ‘‘safe’’ chromosomal sites within the
human genome for transgene integration (Yant et al., 2007).
Ma´te´s and colleagues developed the SB100X hyperactive
mutant transposase, which was shown to be 100-fold more
active than the wild-type SB10 transposase in HeLa cells
under conditions in which the amount of transposon tem-
plate was a limiting factor (Ma´te´s et al., 2009). SB100X was
also shown to support 35–50% stable gene transfer in pri-
mary human CD34þ cells enriched in hematopoietic stem or
progenitor cells that had previously proven difficult to
transfect, and thus, unsupportive of transposition using the
first-generation SB transposon system. In addition, it was
demonstrated that the hyperactive SB100X transposase did
not create any detectable genomic instability in the stably
transfected CD34þ cells, which allowed them to differentiate
into distinct lymphohematopoietic lineages similar to the
nontransfected controls. Of particular interest to the present
study, SB100X promoted far more robust, long-lasting
transgene expression than early-generation hyperactive
transposases in vivo after delivery into the mouse liver by
hydrodynamic injection (Ma´te´s et al., 2009). These results
have highlighted the possibility of using SB-mediated, non-
viral approaches to genetically modify hematopoietic stem
cells ex vivo and hepatocytes in vivo for the treatment of
human diseases. Thus, employing the appropriate hyperac-
tive SB transposase in specific gene transfer paradigms may
provide a means to enhance transposition efficiency, which
in turn could improve a given therapeutic outcome. The ef-
ficiency of the SB100X hyperactive system in the context of
the HSV amplicon delivery paradigm remains to be assessed.
In 2008, after a decade of extensive research, a human
clinical trial was proposed for the treatment of CD19þ B-
lymphoid malignancy by means of autologous transplanta-
tion of T cells that have been genetically modified via the
nonviral SB transposon vector system to express a CD19-
specific chimeric antigen receptor (CAR). In this protocol, in-
vestigators will use the SB11 hyperactive mutant transposase
(Geurts et al., 2003) for stable integration of the CD19-specific
CAR-encoding genetic unit in primary T cells (Singh et al.,
2008). Notably, the hyperactive SB11 transposase has been
used in in vivo studies to enhance plasmid-based transposition
for the treatment of mucopolysaccharidosis I (MPSI;
Aronovich et al., 2007) and also in chromosomal-based
transposition for the discovery of cancer genes (Collier et al.,
2005; Dupuy et al., 2005). Although limited studies conducted
in human cell lines have not revealed genomic instability or
insertional mutagenesis associated with the SB11 hyperactive
transposase, one of the recommendations by the National
Institutes of Health Recombinant DNA Advisory Committee
(NIH RAC) has been to perform extended evaluations of SB11
transposase-modified T cells for possible clonal expansion and
for insertional mutagenesis that could lead to T cell malig-
nancies (Williams, 2008). Thus, it is imperative to conduct
careful preclinical assessments of the in vivo impact of using
hyperactive SB transposase mutants in specific tissue types to
rule out the possibility of such detrimental outcomes.
In utero gene therapy, although invasive in nature, pro-
vides a therapeutic option for early-onset genetic conditions
that manifest themselves during early development. As ob-
served in our study, neuronal stem cells present in the de-
veloping CNS provide an excellent carrier to widely
distribute a therapeutic gene by the HSV/SB amplicon vector
platform. In addition, immune tolerance to the transgene
product and possibly the viral vector can be achieved via
in utero gene transfer because of the naive nature of the host
immune system. This allows for vector persistence and
possibly long-term expression of the delivered transgene
compared with gene transfer into the adult CNS. Hence,
further research in animal models of early-onset neurological
diseases is warranted to assess the safety and efficacy of
HSV/SB amplicon vector-based in utero gene therapy.
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